From Name

From Email

To Name

To Email

Message

Roxadustat for Treatment of Anemia in Patients with CKD

from Nephrology Times

Roxadustat for Treatment of Anemia in Patients with CKD Nephrology Times The oral hypoxia-inducible factor prolyl hydroxylase (HIF-PHI), roxadustat, is in last-stage development for the treatment of anemia in patients with chronic kidney disease (CKD). READ MORE

more